Put Warnings About Liver Damage With Hep C Meds Into Perspective

April 2017

You'll hear about a link between hepatitis C meds and liver damage...especially in patients who also have hepatitis B.

FDA now requires a boxed warning about the risk of hepatitis B reactivation with newer hep C meds...Epclusa, Harvoni, Zepatier, etc.

And a recent report from Institute for Safe Medication Practices warns about rare cases of liver injury and failure tied to these meds.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote